Development of an improved live attenuated antigenic marker CSF vaccine strain candidate with an increased genetic stability

被引:19
|
作者
Holinka, L. G. [1 ,2 ]
Fernandez-Sainz, I. [1 ]
Sanford, B. [1 ]
O'Donnell, V. [1 ,2 ]
Gladue, D. P. [1 ,2 ]
Carlson, J. [1 ]
Lu, Z. [3 ]
Risatti, G. R. [2 ]
Borca, M. V. [1 ]
机构
[1] ARS, Plum Isl Anim Dis Ctr, USDA, Greenport, NY 11944 USA
[2] Univ Connecticut, Dept Pathobiol & Vet Sci, Storrs, CT 06269 USA
[3] DHS, Plum Isl Anim Dis Ctr, Greenport, NY 11944 USA
关键词
Marker vaccine; DIVA strategy; Protection; Minimal protective dose; Vaccine safety; Classical swine fever virus; CLASSICAL SWINE-FEVER; HOG-CHOLERA VIRUS; VIRULENCE DETERMINANT; E-RNS; E2; GLYCOPROTEIN; PESTIVIRUS; ANTIBODIES; NS4B;
D O I
10.1016/j.virol.2014.09.021
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Controlling classical swine fever (CSF) involves vaccination in endemic regions and preemptive slaughter of infected swine herds during epidemics. Live attenuated marker vaccines that confer effective protection against the disease and allow differentiation between infected and vaccinated animals (DIVA) could impact CSF control policies. Previously, we reported the development of FlagT4 virus (FlagT4v), a rationally designed live attenuated marker vaccine. During its vaccine assessment, FlagT4v reverted to a virulent virus during successive passages in piglets. Sequence analysis revealed deletions and substitutions almost exclusively in the areas of El and E2. To improve genetic stability of FlagT4v, we introduced changes in the codon usage in those areas. The newly developed virus, FlagT4Gv, was shown to retain the attenuated phenotype after successive passages in piglets. As observed with FlagT4v, the newly developed FlagT4Gv conferred effective protection against challenge with virulent CSFV at early (7 days) and at late (28 days) times post-vaccination. Published by Elsevier Inc.
引用
收藏
页码:13 / 18
页数:6
相关论文
共 50 条
  • [21] DEVELOPMENT OF LIVE ATTENUATED HEPATITIS-A VACCINE (H2-STRAIN)
    MAO, JS
    CHEN, NL
    HUANG, HY
    CHAI, SA
    DONG, DX
    CAO, YY
    ZHANG, HY
    WU, DM
    ZHANG, SY
    CHINESE MEDICAL JOURNAL, 1992, 105 (03) : 189 - 193
  • [22] DEVELOPMENT OF LIVE, ATTENUATED HEPATITIS-A VACCINE (H2-STRAIN)
    MAO, JS
    VACCINE, 1990, 8 (06) : 523 - 524
  • [23] Extended Preclinical Safety, Efficacy and Stability Testing of a Live-attenuated Chikungunya Vaccine Candidate
    Plante, Kenneth S.
    Rossi, Shannan L.
    Bergren, Nicholas A.
    Seymour, Robert L.
    Weaver, Scott C.
    PLOS NEGLECTED TROPICAL DISEASES, 2015, 9 (09):
  • [24] Phenotypic and genetic characterization of a next generation live-attenuated yellow fever vaccine candidate
    Esson, Raphael
    De Sousa, Emanuel Rodrigues
    Benair, Loic
    Devard, Nicolas
    Soulet, Damien
    Gillet, Audrey
    Bassard, Isabelle
    Falque, Stephanie
    Chareyre, Audrey
    Marmin, Morgane
    Girerd-Chambaz, Yves
    Logvinoff, Carine
    Sanchez, Martha Erika Navarro
    VACCINE, 2022, 40 (38) : 5641 - 5650
  • [25] Attenuation and Stability of CHIKV-NoLS, a Live-Attenuated Chikungunya Virus Vaccine Candidate
    Abeyratne, Eranga
    Freitas, Joseph R.
    Zaid, Ali
    Mahalingam, Suresh
    Taylor, Adam
    VACCINES, 2019, 7 (01)
  • [26] PERU-15, AN IMPROVED LIVE ATTENUATED ORAL VACCINE CANDIDATE FOR VIBRIO-CHOLERAE-01
    KENNER, JR
    COSTER, TS
    TAYLOR, DN
    TROFA, AF
    BARRERAORO, M
    HYMAN, T
    ADAMS, JM
    BEATTIE, DT
    KILLEEN, KP
    SPRIGGS, DR
    MEKALANOS, JJ
    SADOFF, JC
    JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (04): : 1126 - 1129
  • [27] Development of a live-attenuated influenza B ΔNS1 intranasal vaccine candidate
    Wressnigg, Nina
    Voss, Daniel
    Wolff, Thorsten
    Romanova, Julia
    Ruthsatz, Tanja
    Mayerhofer, Ines
    Reiter, Manfred
    Nakowitsch, Sabine
    Humer, Johannes
    Morokutti, Alexander
    Muster, Thomas
    Egorov, Andrej
    Kittel, Christian
    VACCINE, 2009, 27 (21) : 2851 - 2857
  • [28] DEVELOPMENT OF AN ATTENUATED STRAIN FOR JAPANESE ENCEPHALITIS LIVE VIRUS-VACCINE FOR PORCINE USE
    FUJISAKI, Y
    SUGIMORI, T
    MORIMOTO, T
    MIURA, Y
    NATIONAL INSTITUTE OF ANIMAL HEALTH QUARTERLY, 1975, 15 (01) : 15 - 23
  • [29] Characterization of a novel live attenuated infectious bronchitis virus vaccine candidate derived from a Korean nephropathogenic strain
    Lee, Hyun Jeong
    Youn, Ha Na
    Kwon, Ji Sun
    Lee, Youn Jeong
    Kim, Jae Hong
    Lee, Joong Bok
    Park, Seung Yong
    Choi, In Soo
    Song, Chang Seon
    VACCINE, 2010, 28 (16) : 2887 - 2894
  • [30] Development of potentiometric immunosensor for determination of live attenuated Varicella Vaccine: Potency and stability studies
    Mostafa, Moushira M.
    Sedik, Ghada A.
    Elzanfaly, Eman S.
    Nadim, Ahmed H.
    ANALYTICAL BIOCHEMISTRY, 2023, 683